Secondary diabetes mellitus in Prader-Willi syndrome



Prader-Willi Syndrome (PWS) is a rare autosomal dominant disorder on the 15q11.2-q13 chromosome. PWS may impact metabolic, endocrine, and neurologic systems and combine with hypotonia, sleep disturbances, cognitive disability, central adrenal insufficiency, hypothyroidism, hypogonadism, short stature, and other diseases.


Here ,we report a PWS patient with secondary diabetes mellitus. Clinical and laboratory features are summarized.


The patient had typical manifestations of PWS including almond-shaped eyes, narrow temples, narrow nasal bridge, and short hands and feet. Lab test revealed hypogonadism and growth hormone deficiency. SNP array revealed one copy of chromosome 15 q11.2q13.1 was missing, with a length of about 6.4 mbp.


This case emphasizes the importance of considering PWS in the differential diagnosis of an adolescent with diabetes. Antenatal history of neonatal hypotonia and childhood history of feeding disorder are the keys to the diagnosis of PWS.

This is a preview of subscription content, access via your institution.


  1. 1.

    Bohonowych J, Miller J, McCandless SE, Strong TV. The global Prader-Willi syndrome registry: development, launch, and early demographics. Genes (Basel). 2019;10(9):713.

    CAS  Article  Google Scholar 

  2. 2.

    Prader A, Labhart A, Willi H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach myatonieartigem Zustand im Neugeborenenalter. Schweiz Med Wschr. 1956;86:2.

    Google Scholar 

  3. 3.

    Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14:10–26.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Holm VA, et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics. 1993;91:398–402.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Prader A, Willi H. Das Syndrom von Imbezillitat, Adipositas, Muskelhypotonie, Hypogenitalismus, Hypogonadismus und Diabetes mellitus mit "Myatonie"-Anamnese. Kongr Psych Entw-Stor Kindes-Alt. 1963;1:353.

  6. 6.

    Sinnema M, et al. Physical health problems in adults with Prader-Willi syndrome. Am J Med Genet A. 2011;155a:2112–24.

    Article  PubMed  Google Scholar 

  7. 7.

    Butler JV, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T. Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev Med Child Neurol. 2002;44:248–55.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Zipf WB. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. Acta Paediatr Suppl. 1999;88:115–7.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Fintini D, Grugni G, Bocchini S, Brufani C, di Candia S, Corrias A, et al. Disorders of glucose metabolism in Prader-Willi syndrome: results of a multicenter Italian cohort study. Nutr Metab Cardiovasc Dis. 2016;26:842–7.

  10. 10.

    Tsuchiya T, Oto Y, Ayabe T, Obata K, Murakami N, Nagai T. Characterization of diabetes mellitus in Japanese Prader-Willi syndrome. Clin Pediatr Endocrinol. 2011;20:33–8.

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H, et al. Endocrine disorders in children with Prader-Willi syndrome--data from 142 children of the French database. Horm Res Paediatr. 2010;74:121–8.

  12. 12.

    Yang A, Kim J, Cho SY, Jin DK. Prevalence and risk factors for type 2 diabetes mellitus with Prader-Willi syndrome: a single center experience. Orphanet J Rare Dis. 2017;12:146.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr. 2000;137:42–9.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    L'Allemand D, Eiholzer U, Schlumpf M, Torresani T, Girard J. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome. Horm Res. 2003;59:239–48.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Bakker NE, Kuppens RJ, Siemensma EPC, Tummers-de Lind van Wijngaarden RFA, Festen DAM, Bindels-de Heus GCB, et al. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab. 2013;98:4013–22.

  16. 16.

    Hoybye C. Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition. Acta Paediatr. 2015;104:422–7.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Campbell PJ, Gerich JE. Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab. 1990;70:1114–8.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab. 2008;93:4183–97.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Miller JL, Linville TD, Dykens EM. Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. J Pediatr Endocrinol Metab. 2014;27:23–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Scheimann AO, Lee PDK, Ellis KJ. In: Butler MG, Lee PDK, Whitman BY, editors. Management of Prader-Willi Syndrome. New York: Springer; 2006. p. 153–200.

    Google Scholar 

  21. 21.

    Butler MG. Management of obesity in Prader-Willi syndrome. Nat Clin Pract Endocrinol Metab. 2006;2:592–3.

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2011;96:E1314–9.

  23. 23.

    Salehi P, Hsu I, Azen CG, Mittelman SD, Geffner ME, Jeandron D. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr Obes. 2017;12:221–8.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Seetho IW, Jones G, Thomson GA, Fernando DJ. Treating diabetes mellitus in Prader-Willi syndrome with Exenatide. Diabetes Res Clin Pract. 2011;92:e1–2.

    Article  PubMed  Google Scholar 

  25. 25.

    Cyganek K, Koblik T, Kozek E, Wojcik M, Starzyk J, Malecki MT. Liraglutide therapy in Prader-Willi syndrome. Diabet Med. 2011;28:755–6.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, Ito S. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Endocr J. 2012;59:889–94.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Fintini D, Grugni G, Brufani C, Bocchini S, Cappa M, Crinò A. Use of GLP-1 receptor agonists in Prader-Willi syndrome: report of six cases. Diabetes Care. 2014;37:e76–7.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Hauber M, Stratmann B, Hoedebeck-Stuntebeck N, Tschoepe D. MedicalmanagementforadultswithPrader-Willisyndrome. Metab Syndr Relat Disord. 2013;11(6):392–6.

    CAS  Article  Google Scholar 

  29. 29.

    Kato E, Kimura M, Okuda T, Toyoda M, Fukagawa M. Behavior modificationmaintenancewithlong-termbloodglucoseandweight management in Prader-Willi syndrome complicated with diabetes:team management approach combined with pharmacological treat-ment. Case Rep Med. 2019;19:1–7.

    CAS  Article  Google Scholar 

  30. 30.

    Crinò A, Grugni G. Update on diabetes mellitus and glucose metabolism alterations in Prader-Willi syndrome. Curr Diab Rep. 2020 Feb 6;20(2):7.

    Article  PubMed  Google Scholar 

  31. 31.

    Tan Q, Orsso CE, Deehan EC, Triador L, Field CJ, Tun HM, et al. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: a narrative review. Obes Rev. 2020 May;21(5):e12992.

  32. 32.

    Aycan Z, Bas VN. Prader-Willi syndrome and growth hormone deficiency. J Clin Res Pediatr Endocrinol. 2014;6:62–7.

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Longhi S, Grugni G, Gatti D, Spinozzi E, Sartorio A, Adami S, et al. Adults with Prader-Willi syndrome have weaker bones: effect of treatment with GH and sex steroids. Calcif Tissue Int. 2015;96:160–6.

  34. 34.

    Eiholzer U, Grieser J, Schlumpf M, l'Allemand D. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. Horm Res. 2007;68:178–84.

    CAS  Article  PubMed  Google Scholar 

Download references


Authors acknowledge assistance of department of endocrinology of the first affiliated hospital of Xi'an Jiaotong University.

Author information



Corresponding author

Correspondence to Juan Liu.

Ethics declarations

Informed consent

Has been signed.

Source of support


Conflict of interest

Authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gao, C., Yao, X. & Liu, J. Secondary diabetes mellitus in Prader-Willi syndrome. Int J Diabetes Dev Ctries (2021).

Download citation


  • Prader-Willi syndrome
  • Secondary diabetes mellitus
  • Growth hormone deficiency
  • Hypogonadism
  • Case report